Related Experiment Video
Updated: Mar 22, 2026
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Steering through complexity: management approaches in multiple sclerosis
Bruce A C Cree1, Hans-Peter Hartung
1aDepartment of Neurology, Multiple Sclerosis Center, University of California, San Francisco, California, USA bDepartment of Neurology and Center for Neuropsychiatry, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
Purpose Of Review:
This review evaluates current and late-phase developing therapies for multiple sclerosis in regard to therapeutic efficacy and patient safety in light of recent published and presented observations from 2015.
Recent Findings:
We describe data that provide supportive evidence for comparisons of therapeutic efficacy of multiple sclerosis therapies and review available data on rare but serious adverse events associated with these therapies.
Summary:
Serious adverse events that are sometimes rare and unpredictable may substantially alter current approaches to multiple sclerosis treatments. New therapies that have proved superior effects compared with older therapies will also impact multiple sclerosis treatment practice in the near future.
Insights
New multiple sclerosis (MS) therapies show improved efficacy and safety. Rare adverse events with MS treatments may alter current clinical practice, impacting future treatment decisions.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system.
- Current therapeutic strategies aim to reduce disease activity and manage symptoms.
- Ongoing research focuses on developing novel treatments with improved efficacy and safety profiles.
Purpose of the Study:
- To evaluate the therapeutic efficacy of current and late-phase developing therapies for multiple sclerosis.
- To assess patient safety profiles of these multiple sclerosis therapies.
- To provide an overview based on observations published and presented since 2015.
Main Methods:
- Systematic literature review of published and presented data from 2015 onwards.
- Analysis of clinical trial data and real-world evidence regarding therapeutic efficacy.
- Evaluation of reported adverse event data, focusing on rare but serious events.
Main Results:
- Emerging therapies demonstrate superior efficacy compared to older treatments for multiple sclerosis.
- Data support direct comparisons of therapeutic effectiveness across various multiple sclerosis medications.
- Rare but serious adverse events associated with multiple sclerosis therapies have been identified and reviewed.
Conclusions:
- Newer multiple sclerosis therapies are poised to significantly impact clinical practice due to enhanced efficacy.
- Understanding and managing rare adverse events is crucial for optimizing patient safety in multiple sclerosis treatment.
- The evolving landscape of multiple sclerosis therapeutics necessitates continuous evaluation of efficacy and safety.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:23Atherosclerosis IV: Nursing Management
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:26Atherosclerosis III: Management
01:15Methods of Documentation VI: Case Management Model
For example, a patient with a chronic...